ATXA Therapeutics is a clinical-stage pharmaceutical company committed to the advancement of innovative, life-changing treatments for cardiopulmonary diseases. Our research focuses on developing novel, antagonists of the Thromboxane Receptor (TP), a key driver of disease within the heart & lungs.
ATXA’s world class team encompasses leading experts in the relevant fields, including scientists, clinicians, and commercial strategists with extensive experience and noted successes in the field of drug development and commercialization.
Driven by innovative research, our aim is to bring accessible, affordable and life-changing treatments to patients with cardiopulmonary diseases, offering them new hope and bettering their lives.
Founded by Professor Therese Kinsella in 2015, ATXA is the culmination of over 20 years of research and extensive, prestigious funding, along with a proven record in elucidating the biology and signalling of the human prostanoid receptors in disease settings.
Headquartered in Dublin, Ireland, ATXA aims to develop novel therapies for the treatment of cardiopulmonary indications. ATXA seeks to advance clinical trials and secure marketing authorization for therapies that display significant improvements over existing standard-of-care and address unmet medical needs.
Through our R&D, ATXA has built a pipeline of novel, highly selective small molecule drugs and has validated their efficacy potential in preclinical models of cardiopulmonary, acute pulmonary inflammation, oncology, and other diseases.
Our current focus is the development of our lead pipeline compound NTP42 for the treatment of Pulmonary Arterial Hypertension (PAH), where we aim to offer improved treatment options to the prescribing physician and new hope for the PAH patient.
In addition to its external investors, ATXA has received substantial grants from Enterprise Ireland, and through the European Union’s prestigious Horizon 2020 SME Instrument funding scheme.
Our Drug Pipeline is protected by a growing global patent estate and we have secured Orphan Designation from the EMA (Europe) and the FDA (USA) for our lead drug NTP42 for our initial target indication Pulmonary Arterial Hypertension (PAH).